期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 54, 期 33, 页码 9659-9662出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201503720
关键词
antiproliferation; cancer; drug design; hormones; protein degradation
资金
- NIH [T32GM067543, F32GM10052101, R01CA139818, R01AIO84140]
- DoD [W81XWH-12-1-0484]
Androgen receptor (AR)-dependent transcription is a major driver of prostate tumor cell proliferation. Consequently, it is the target of several antitumor chemotherapeutic agents, including the AR antagonist MDV3100/enzalutamide. Recent studies have shown that a single AR mutation (F876L) converts MDV3100 action from an antagonist to an agonist. Here we describe the generation of a novel class of selective androgen receptor degraders (SARDs) to address this resistance mechanism. Molecules containing hydrophobic degrons linked to small-molecule AR ligands induce AR degradation, reduce expression of AR target genes and inhibit proliferation in androgen-dependent prostate cancer cell lines. These results suggest that selective AR degradation may be an effective therapeutic prostate tumor strategy in the context of AR mutations that confer resistance to second-generation AR antagonists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据